In order to explore underlying mechanisms of resistance to ADCC that may be shared across cancer type and antibody target, we used our model system to re-derive ADCC-resistant A431 cells and generate additional ADCC-resistant variants using the HER2-overexpressing ovarian carcinoma cell-line SKOV3 and the EGFR-overexpressing head and neck squamous cell carcinoma cell line FaDu. This evidence concerns the gene ERBB2 and cancer.